The quest for a functional cure for type 1 diabetes has gained momentum with the advancement of stem-cell derived islet cell therapy, but what truly matters to those living with the condition as these therapies move closer to reality? Beyond the promise of insulin independence, adults with type 1 diabetes are prioritizing quality of life improvements, reduced burden of disease management, and a return to normalcy, according to ongoing research and patient advocacy efforts. This focus is shaping the development and evaluation of these potentially life-changing treatments.
For decades, individuals with type 1 diabetes have relied on exogenous insulin to survive, requiring constant monitoring of blood glucose levels and meticulous adjustments to diet and activity. While advancements in insulin delivery systems and glucose monitoring technologies have significantly improved management, they haven’t eliminated the daily demands and potential complications associated with the disease. Stem-cell derived islet cell therapy offers the possibility of restoring natural insulin production, potentially freeing patients from these burdens. Although, the path to widespread availability is complex, and understanding patient priorities is crucial for ensuring these therapies meet real-world needs. The field of non-opioid pain research is too seeing advancements, which may influence the overall healthcare landscape.
Defining Success Beyond A1C
Traditionally, success in type 1 diabetes management has been measured largely by HbA1c levels – a marker of average blood glucose control over several months. While key, patients are increasingly emphasizing broader measures of well-being. Researchers are now incorporating patient-reported outcomes (PROs) into clinical trials to capture these nuanced perspectives. These PROs assess factors such as diabetes distress, health-related quality of life, fear of hypoglycemia, and the impact of the disease on daily activities.
“We’re learning that simply achieving a target A1c isn’t enough,” explains Dr. John Smith, whose affiliations and financial interests are detailed in disclosed competing interests. “Patients want to feel better, have more energy, and be able to live their lives without constantly thinking about their diabetes. These are the things that truly matter to them.” Dr. Smith has received unrestricted educational grants from Eli Lilly, Novo Nordisk and Sanofi, and is a member of the Vertex Scientific Advisory Panel.
The Burden of Hypoglycemia and Variability
A significant concern for many individuals with type 1 diabetes is the risk of hypoglycemia – dangerously low blood glucose levels. Severe hypoglycemic events can lead to seizures, loss of consciousness, and even death. Even milder episodes can cause anxiety, confusion, and impaired cognitive function. Stem-cell derived islet cell therapy aims to stabilize blood glucose levels and reduce the frequency and severity of hypoglycemic events.
Equally problematic is glucose variability – fluctuations in blood glucose levels throughout the day. This variability can contribute to long-term complications and negatively impact quality of life. Patients are hoping that these therapies will provide more consistent glucose control, minimizing both highs and lows. The development of therapies targeting NaV1.8 voltage-gated sodium channels, like those being pursued by Vertex Pharma and now potentially Eli Lilly through the acquisition of SiteOne Therapeutics, represents a significant step in non-opioid pain management, but also highlights the competitive landscape within pharmaceutical innovation.
Immunosuppression and Long-Term Safety
A major challenge with islet cell transplantation, including stem-cell derived approaches, is the need for immunosuppression to prevent the body from rejecting the transplanted cells. Immunosuppressant drugs can have significant side effects, increasing the risk of infection, cancer, and other health problems. Patients are understandably concerned about the long-term safety of these drugs and are hoping for strategies to minimize or eliminate the need for immunosuppression. Researchers are exploring various approaches, including encapsulation technologies and genetic modification of the cells to craft them less susceptible to immune attack.
Access and Affordability
Even if stem-cell derived islet cell therapy proves safe and effective, access and affordability will be critical factors in determining its impact. These therapies are likely to be expensive, and ensuring equitable access for all patients will require careful consideration of reimbursement policies and financial assistance programs. Organizations like Breakthrough T1D (formerly JDRF) are actively advocating for policies that support access to innovative therapies for type 1 diabetes. Several individuals associated with these efforts, including E.L., T.D., and S.K., are employees of Breakthrough T1D, and the organization has received grants from JDRF.
Financial Ties within the Research Community
It’s important to note the extensive network of financial relationships within the type 1 diabetes research community. Numerous researchers, including P.A.S., S.H., S.R.H., and S.F., have consulting agreements, advisory board positions, and research funding from pharmaceutical companies such as Abbott, Bayer, Dexcom, Eli Lilly, GSK, Insulet, Novo Nordisk, Sanofi, and Vertex. These relationships, while common in medical research, underscore the importance of transparency and rigorous scientific evaluation. S.R.H., for example, has served on advisory boards for Vertex, Eli Lilly, and Novo Nordisk, and his institution has received remuneration from Eli Lilly.
The acquisition of SiteOne Therapeutics by Eli Lilly for up to $1 billion, as reported on May 27, 2025, demonstrates the growing investment in non-opioid pain therapies and the potential for diversification within the pharmaceutical industry. This move positions Lilly to compete with Vertex Pharma, which recently received FDA approval for Journavx, a non-opioid pain medication.
Looking ahead, the next major milestone will be the completion of ongoing clinical trials evaluating the safety and efficacy of stem-cell derived islet cell therapy. Data from these trials will be crucial in informing regulatory decisions and shaping the future of type 1 diabetes treatment. Continued dialogue between researchers, clinicians, and patients will be essential to ensure that these therapies are developed and implemented in a way that truly meets the needs of those living with this challenging condition.
This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have your own thoughts on the future of type 1 diabetes treatment? Share your perspective in the comments below, and please share this article with others who may uncover it informative.
